Prescribing Information for the Patient
Invokana 100 mg Film-Coated Tablets
Invokana 300 mg Film-Coated Tablets
canagliflozina
Read this entire prescribing information carefully before starting to take this medicine, as it contains important information for you.
Invokana contains the active ingredient canagliflozina, which belongs to a group of medications known as “anti-hyperglycemics.”
Invokana is used:
This medication works by removing a greater amount of sugar from your body through your urine. This reduces the amount of sugar in your blood and may help prevent heart disease in patients with type 2 diabetes mellitus (DMT2). It also helps to delay the deterioration of kidney function in patients with DMT2 through a mechanism that goes beyond reducing blood glucose levels.mellitustype2 (DMT2). Also helps to delay the deterioration of kidney function in patients with DMT2 through a mechanism that goes beyond reducing blood glucose levels..
Invokana is administered as monotherapy or in combination with other medications you may already be taking to treat your type 2 diabetes (such as metformin, insulin, a DPP-4 inhibitor [such as sitagliptin, saxagliptin, or linagliptin], a sulfonylurea [such as glimepiride or glipizide], or pioglitazone) that reduce blood sugar levels. You may already be taking one or more of these medications to treat your type 2 diabetes.
It is essential that you do not stop following the dietary and exercise recommendations provided by your doctor or nurse.
What is type 2 diabetes?
Type 2 diabetes is a disorder in which the body does not produce enough insulin and the insulin it produces does not function properly. It can also be that your body produces too much sugar.
When this occurs, sugar (glucose) accumulates in the blood. This can produce serious medical diseases, such as heart disease, kidney disease, blindness, and amputations.
Do not take Invokana:
Consult your doctor, pharmacist, or nurse before starting to take Invokana and during treatment:
If any of the above situations apply to you (or if you are unsure), speak with your doctor, pharmacist, or nurse before taking this medication.
Renal function
You will have a kidney function review through a blood test before starting to take and while taking this medication.
Urine glucose
Due to how this medication works, your urine will test positive for sugar (glucose) while you are taking this medication.
Children and adolescents
Invokana is not recommended for children or adolescents under 18 years old.
Other medications and Invokana
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. This medication may affect the mechanism of action of other medications. Additionally, other medications may affect the mechanism of action of this medication.
In particular, inform your doctor if you are taking any of the following medications:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication. Invokana should not be used during pregnancy. Consult your doctor on the best way to stop Invokana and control your blood sugar levels as soon as you know you are pregnant.
You should not take this medication if you are breastfeeding. Consult your doctor if you need to stop taking this medication or if you need to stop breastfeeding.
Driving and operating machinery
Invokana has no or negligible influence on your ability to drive, ride a bicycle, or use tools or machinery. However, some patients may experience dizziness or drowsiness, which may affect your ability to drive, ride a bicycle, or use tools or machinery.
Taking Invokana with other diabetes medications called sulfonylureas (such as glimepiride or glipizide) or insulin may increase the risk of low blood sugar (hypoglycemia). Symptoms include blurred vision, tingling in the lips, tremors, sweating, paleness, mood changes, anxiety, or confusion. This may affect your ability to drive, ride a bicycle, and use tools or machinery. Inform your doctor as soon as possible if you experience any symptoms of low blood sugar.
Invokana contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Invokana contains sodium
This medication contains less than 1 mmol (23 mg) of sodium per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
How much to take
When taking this medication
Your doctor may prescribe Invokana with another anti-hyperglycemic medication.
Remember to take all your medications as instructed by your doctor to achieve the best results for your health.
Diet and exercise
To control your diabetes, you still need to follow the advice of your doctor, pharmacist, or nurse regarding diet and exercise. In particular, if you follow a weight-control diabetic diet, you should continue it while taking this medication.
If you take more Invokana than you should
If you take more medication than you should, consult your doctor or go immediately to the nearest hospital.
If you forget to take Invokana
If you interrupt treatment with Invokana
Your blood sugar concentration may increase if you stop taking this medication. Do not stop using this medication without first talking to your doctor.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Invokana and consult a doctor or go immediately to the nearest hospital if you notice any of the following serious side effects:
Severe allergic reaction (rare, may affect up to 1 in 1,000 people)
Possible symptoms of a severe allergic reaction may include:
Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)
These are the symptoms of diabetic ketoacidosis (see also section 2):
This can occur regardless of your blood glucose levels. Diabetic ketoacidosis may occur more frequently as kidney function worsens. Your doctor may decide to temporarily or permanently discontinue Invokana treatment.
Dehydration (infrequent, may affect 1 in 100 people)
Possible symptoms of dehydration are:
- Dizziness or vertigo
- Loss of consciousness (fainting), dizziness, or fainting when standing up
- Very dry or sticky mouth, intense thirst
- Feeling extremely tired or weak
- Infrequent or no urination
- Rapid heartbeat.
Inform your doctor as soon as possible if you experience any of the following side effects:
Hypoglycemia (very common, may affect more than 1 in 10 people)
Possible symptoms of low blood sugar are:
- Blurred vision
- Tingling in the lips
- Trembling, sweating, paleness
- Change in mood or feeling anxious or confused.
Your doctor will explain how to treat low blood sugar and what to do if you experience any of the above symptoms.
Urinary tract infections (frequent, may affect up to 1 in 10 people)
Although infrequent, if you notice blood in your urine, inform your doctor immediately.
Other side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Infrequent (may affect up to 1 in 100 people)
Unknown frequency (cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational notification system included in theAppendix V.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack in the box after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Do not use this medication if you observe visible signs of deterioration or tampering.
Medications should not be disposed of through drains or trash. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Invokana
-Each tablet contains canagliflozina hemihidrato, equivalent to 100 mg or 300 mg of canagliflozina.
Appearance of the product and contents of the pack
Invokana is available in pre-cut PVC/aluminum blisters. The pack sizes are cartons of 10 x 1, 30 x 1, 90 x 1, or 100 x 1 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse
Belgium
Responsible for manufacturing
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina
Italy
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Menarini Benelux NV/SA Tel/Tel: +32 (0)2 721 4545 | Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 |
Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: +32 (0)2 721 4545 | |
Czech Republic Berlin-Chemie/A.Menarini Czech Republic s.r.o. Tel: +420 267 199 333 | Magyarország Janssen‑Cilag Kft. Tel.: +36 1 884 2858 |
Denmark Berlin-Chemie AG Tlf: +45 78 71 31 21 | Malta AM MANGION LTD. Tel: +356 2397 6333 |
Germany Janssen‑Cilag GmbH Tel: +49 2137 955‑955 | Netherlands Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Estonia UAB "JOHNSON & JOHNSON" Estonian branch Tel: +372 617 7410 | Norway Berlin-Chemie AG Tlf: +45 78 71 31 21 |
Greece MENARINI HELLAS AE Tηl: +30 210 8316111-13 | Austria A. Menarini Pharma GmbH Tel: +43 1 879 95 85-0 |
Spain Laboratorios Menarini, S.A. Tel: +34 93 462 88 00 | Poland Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal A. Menarini Portugal – Farmacêutica, S.A. Tel: +351 210 935 500 |
Croatia Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | Romania Johnson & Johnson Romania SRL Tel: +40 21 207 1800 |
Ireland A.Menarini Pharmaceuticals Ireland Ltd Tel: +353 1 284 6744 | Slovenia Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 |
Iceland Janssen‑Cilag AB c/o Vistor hf. Tel: +354 535 7000 | Slovakia Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o Tel: +421 2544 30730 |
Italy Laboratori Guidotti S.p.A. Tel: +39 050 971011 | Finland Berlin-Chemie/A. Menarini Finland Oy Tel: +358 403 000 760 |
Cyprus MENARINI HELLAS AE Tηl: +30 210 8316111-13 | Sweden Berlin-Chemie AG Tfn: +45 78 71 31 21 |
Latvia UAB "JOHNSON & JOHNSON" filiale Latvia Tel: +371 678 93561 | United Kingdom (Northern Ireland) A. Menarini Farmaceutica Internazionale S.R.L. Tel: +44 (0)1628 856400 |
Last date of revision of the summary of product characteristics:June 2023.
Other sources of information
Detailed information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu,and on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.